Volume | 91,694 |
|
|||||
News | - | ||||||
Day High | 1.82 | Low High |
|||||
Day Low | 1.65 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Virax Biolabs Group Ltd | VRAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.77 | 1.65 | 1.82 | 1.81 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
602 | 91,694 | US$ 1.73 | US$ 158,969 | - | 0.60 - 4.599 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:08:54 | 293 | US$ 1.6901 | USD |
Virax Biolabs Group Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.64M | 1.56M | - | 9k | -5.46M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Virax Biolabs News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRAX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.65 | 2.00 | 1.53 | 1.78 | 544,187 | 0.0401 | 2.43% |
1 Month | 0.84 | 2.80 | 0.75 | 1.94 | 4,600,400 | 0.8501 | 101.20% |
3 Months | 0.78 | 2.80 | 0.60 | 1.92 | 1,525,725 | 0.9101 | 116.68% |
6 Months | 1.46 | 2.80 | 0.60 | 1.86 | 784,300 | 0.2301 | 15.76% |
1 Year | 4.506 | 4.599 | 0.60 | 2.08 | 466,390 | -2.82 | -62.49% |
3 Years | 200.00 | 290.00 | 0.60 | 35.44 | 1,114,011 | -198.31 | -99.15% |
5 Years | 200.00 | 290.00 | 0.60 | 35.44 | 1,114,011 | -198.31 | -99.15% |
Virax Biolabs Description
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. |